help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints, Permissions and Rights
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Desai, R. K.
Right arrow Articles by Prabhakar, B. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Desai, R. K.
Right arrow Articles by Prabhakar, B. S.

Journal of Clinical Endocrinology & Metabolism, Vol 77, 658-663, Copyright © 1993 by Endocrine Society

ARTICLES

Dual mechanism of perturbation of thyrotropin-mediated activation of thyroid cells by antibodies to the thyrotropin receptor (TSHR) and TSHR- derived peptides

RK Desai, JS Dallas, MK Gupta, GS Seetharamaiah, JL Fan, K Tahara, LD Kohn and BS Prabhakar
Department of Microbiology, University of Texas Medical Branch, Galveston, 77555.

To further define the epitopes with which anti-TSH receptor (anti-TSHR) antibodies react and mediate their biological effects, we used antibodies against the extracellular domain of TSHR (ETSHR) protein and nine peptides derived from the ETSHR. Peptides were chosen based on their predicted immunogenicity as well as their uniqueness to the TSHR. Antipeptide antibodies showed varying degrees of reactivity against ETSHR, with antipeptide-2-(352-366) and -3A-(357-372) showing relatively stronger reactivity with the receptor. Antibodies were tested for their ability to stimulate thyroid cells and were found to be ineffective in causing both cAMP release and iodide uptake. However, anti-3A and anti-ETSHR showed blocking TSHR antibody (TSHRAb) activities of 76.9% and 79.7%, respectively, which were significantly different (P < 0.005) compared to that of preimmune serum. Anti-2 and - 91 (AA 32-46) also showed blocking TSHRAb activities of 37.5% and 35.6%, respectively (P < 0.05). Antisera were also tested for their ability to block TSH binding to thyroid membranes in a RRA. Anti-ETSHR, but not any of the antipeptide antibodies, displayed TSH binding inhibitory immunoglobulin activity. These findings suggest that there might be different mechanisms that mediate blocking TSHR antibody activity. One mechanism involves the inhibition of TSH binding to the receptor, and the other probably involves a step subsequent to TSH binding.


This article has been cited by other articles:


Home page
 EndocrinologyHome page
S. P. Singh, D. McDonald, T. J. Hope, and B. S. Prabhakar
Upon Thyrotropin Binding the Thyrotropin Receptor Is Internalized and Localized to Endosome
Endocrinology, February 1, 2004; 145(2): 1003 - 1010.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
B. Rapoport, G. D. Chazenbalk, J. C. Jaume, and S. M. McLachlan
The Thyrotropin (TSH)-Releasing Hormone Receptor: Interaction with TSH and Autoantibodies
Endocr. Rev., December 1, 1998; 19(6): 673 - 716.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
S. Kikuoka, N. Shimojo, K.-I. Yamaguchi, Y. Watanabe, A. Hoshioka, A. Hirai, Y. Saito, K. Tahara, L. D. Kohn, N. Maruyama, et al.
The Formation of Thyrotropin Receptor (TSHR) Antibodies in a Graves' Animal Model Requires the N-Terminal Segment of the TSHR Extracellular Domain
Endocrinology, April 1, 1998; 139(4): 1891 - 1898.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1993 by The Endocrine Society